Skip to content
← Full study record

NCT00743262 · MORE INFO

Limitations, agreements, and source contact

Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis · Source last updated 2023-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Provox ActiValve users have short device life with normal indwelling prostheses (and hence use the Provox ActiValve). Therefore, the device life measured in this patient group is very short and not representative of the normal Provox Vega user.
point Of Contact
email
f.hilgers@nki.nl
organization
Netherlands Cancer Institute
phone
+31-20-5252550
title
Prof. Dr. F.J.M. Hilgers
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Provox ActiValve users have short device life with normal indwelling prostheses (and hence use the Provox ActiValve). Therefore, the device life measured in this patient group is very short and not representative of the normal Provox Vega user.
point Of Contact
email
f.hilgers@nki.nl
organization
Netherlands Cancer Institute
phone
+31-20-5252550
title
Prof. Dr. F.J.M. Hilgers

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice